Evanston Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-5,733
Closed -$240K 73
2018
Q3
$240K Buy
+5,733
New +$221K 0.05% 62
2017
Q1
Sell
-216,088
Closed -$6.66M 67
2016
Q4
$6.66M Buy
216,088
+13,276
+7% +$405K 2.05% 24
2016
Q3
$6.52M Sell
202,812
-3,877
-2% -$130K 2.04% 20
2016
Q2
$6.91M Buy
206,689
+202
+0.1% +$6.45K 2.25% 9
2016
Q1
$5.81M Buy
206,487
+5,408
+3% +$154K 1.91% 31
2015
Q4
$6.16M Buy
201,079
+2,881
+1% +$90.6K 2.15% 24
2015
Q3
$5.91M Buy
198,198
+9,686
+5% +$311K 1.96% 24
2015
Q2
$6M Sell
188,512
-2,423
-1% -$79K 1.97% 17
2015
Q1
$6.3M Sell
190,935
-12,004
-6% -$382K 2.06% 11
2014
Q4
$6M Buy
202,939
+4
+0% +$115 2.12% 17
2014
Q3
$5.69M Buy
202,935
+10,416
+5% +$292K 1.93% 20
2014
Q2
$5.42M Buy
192,519
+10,025
+5% +$286K 1.88% 23
2014
Q1
$5.56M Sell
182,494
-1,890
-1% -$56.4K 1.99% 10
2013
Q4
$5.36M Buy
184,384
+4,714
+3% +$137K 2.02% 22
2013
Q3
$4.9M Buy
179,670
+7,405
+4% +$201K 1.97% 21
2013
Q2
$4.58M Buy
+172,265
New +$4.76M 2.03% 22

Other funds holding PFE

Evanston Advisors's PFE Position: Q4 2018 in Review

Evanston Advisors sold out of Pfizer (PFE) in Q4 2018, closing a stake of 5,733 shares — an estimated $240K sold.

Evanston Advisors first reported a position in PFE in Q2 2013 and held it in 16 quarters. The position peaked at $6.91M in Q2 2016. 2,403 funds tracked by Wall St. Rank hold PFE as of Q4 2018.

  • Evanston Advisors reported no remaining Pfizer position as of Q4 2018 after selling out during the quarter.
  • Evanston Advisors sold 5,733 Pfizer shares in Q4 2018, an estimated $240K.
  • Evanston Advisors first reported a position in Pfizer in Q2 2013 and held it in 16 quarters.
  • Evanston Advisors's Pfizer position peaked at $6.91M in Q2 2016.
  • 2,403 funds tracked by Wall St. Rank held Pfizer as of Q4 2018.

Based on Evanston Advisors's 13F filing for Q4 2018, filed 11 Feb 2019.